Clinical Trials · NCT06857942
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 200
- Start date
- Mar 2025
- Locations
- 40 sites, United States
- Primary endpoint
- Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1)